The incidence of non-AIDS-defining cancers (NADCs) in HIV-positive patients is increasing, and pharmacists should understand and apply pharmacokinetic parameters in order to identify potential interactions and recommend change in therapy or modifications in dosing and/or administration to aid medical oncologists in choosing the right drug at the right dose given at the right time.

It is important for practitioners to understand what factors influence successful stem cell mobilization in preparation for a transplant. They should also be familiar with the agents used in this process.

Oncology pharmacists are vital members of the oncology team with specialized knowledge of anticancer therapy and can help navigate therapeutic interventions, contributing to selection, dosing, monitoring, evaluation, and education of medications to improve oral immune-related adverse event outcomes.

Learn about the challenges associated with the management of transformed indolent lymphomas and the recent advances in management to help you to incorporate novel therapies into routine clinical practice in the appropriate patient population to improve clinical outcomes.

Learn about the recent advances as well as the challenges involved in the diagnosis and management of classical hairy cell leukemia (HCL) and HCL-variant.

This topic will help fill the gap between current and ideal practice by reviewing examples and best practice recommendations that pharmacists can implement in collaboration with interprofessional team members to improve resource utilization, patient safety, and quality of care.

The flurry of changes to the PARPi indications can cause considerable confusion in clinical practice. It may be difficult for health care professionals to keep track of the emerging data and understand how to apply it to patient care. It is important that health care professionals, including pharmacists, are able to educate their patients on the risks vs. benefits of these agents to help empower them to make informed decisions regarding their treatment.

Learn about the results of recent trials, updates to NCCN Guideline recommendations, and common supportive care needs, so that you can provide optimal management for patients with metastatic prostate cancer.

Advances in pharmacogenomics are widespread in the treatment of cancer. The ongoing research in pharmacogenomics has played a vital role in the diagnosis and treatment of oncologic disease states. It is imperative for the interprofessional oncology care team to have a strong understanding of pharmacogenomics and the ability to correctly apply the standard of care for their patients.